GSK
GSK Big PharmaGSK is a major pharmaceutical company focused on Respiratory, Infectious Disease, Oncology. Key products include NUCALA.
FDA Novel Drug Designations
(2017-2025)GSK at a Glance
- Fast trial execution (8 months median completion)
Upcoming FDA Decisions
Full Calendar →GSK's Key Drugs
GSK's core commercial portfolio centers on NUCALA, BLUJEPA, JEMPERLI, spanning Respiratory and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Asthma
Urinary Tract Infection
Endometrial Cancer
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
GSK's Recent FDA Approvals
GSK secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
GSK's Therapeutic Areas
GSK's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Infectious Disease, across 17 biologic and 30 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GSK's Top Competitors
GSK's closest competitors by therapeutic-area and drug-target overlap include Merck, Johnson & Johnson, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GSK Pipeline Snapshot
GSK has 1142 active clinical programs from ClinicalTrials.gov — 322 Phase 3, 255 Phase 2 and 565 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/2 completed
- • Speed: 8 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (17)
Company Info
- First Approval
- 1949-03-28
- Latest
- 2026-08-21
- Applications
- 193
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges